Ankylosing Spondylitis (Bekhterev’s Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Ankylosing spondylitis is a type of arthritis that affects the spine. Ankylosing spondylitis symptoms include pain and stiffness from the neck down to the lower back. The spine’s bones (vertebrae) may grow or fuse together, resulting in a rigid spine.

The Ankylosing Spondylitis pipeline drugs market research report provides comprehensive information on the therapeutics under development for ankylosing spondylitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases.

Ankylosing Spondylitis Pipeline Drugs Market Segmentation by Targets

The key targets of the ankylosing spondylitis pipeline drugs market are Tumor Necrosis Factor, Interleukin 17A, Lymphotoxin Alpha, Tyrosine Protein Kinase JAK1, Interleukin 17F, Interleukin 17, MAP Kinase Activated Protein Kinase 2, Mitogen Activated Protein Kinase 1, and Granulocyte Macrophage Colony Stimulating Factor. Tumor Necrosis Factor is the target with the highest number of ankylosing spondylitis pipeline drugs in development in 2022.

 Ankylosing Spondylitis Pipeline Drugs Market Analysis, by Targets

 Ankylosing Spondylitis Pipeline Drugs Market Analysis, by Targets

For more target insights into the ankylosing spondylitis pipeline drugs market, download a free report sample

Ankylosing Spondylitis Pipeline Drugs Market Segmentation by Mechanisms of Action

The key mechanisms of action of the ankylosing spondylitis pipeline drugs market are Tumor Necrosis Factor Inhibitor, Interleukin 17A Inhibitor, Lymphotoxin Alpha Inhibitor, Tyrosine Protein Kinase JAK1 Inhibitor, Interleukin 17 Inhibitor, Interleukin 17F Inhibitor, and MAP Kinase Activated Protein Kinase 2 Inhibitor. The Tumor Necrosis Factor Inhibitor MoA has the highest number of ankylosing spondylitis pipeline drugs in development in 2022.

 Ankylosing Spondylitis Pipeline Drugs Market Analysis, by Mechanisms of Action

 Ankylosing Spondylitis Pipeline Drugs Market Analysis, by Mechanisms of Action

For more mechanisms of action insights into the ankylosing spondylitis pipeline drugs market, download a free report sample

Ankylosing Spondylitis Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the ankylosing spondylitis pipeline drugs market are subcutaneous, intravenous, oral, parenteral, and topical. Subcutaneous was the most common RoA for ankylosing spondylitis pipeline drugs in development in 2022.

 Ankylosing Spondylitis Pipeline Drugs Market Analysis, by Routes of Administration

 Ankylosing Spondylitis Pipeline Drugs Market Analysis, by Routes of Administration

For more routes of administration insights into the ankylosing spondylitis pipeline drugs market, download a free report sample

Ankylosing Spondylitis Pipeline Drugs Market Segmentation by Molecule Types

The key molecule types in the ankylosing spondylitis pipeline drugs market are monoclonal antibody, small molecule, fusion protein, protein, small molecule, synthetic peptide, and others. Monoclonal antibody is the most common molecule type for ankylosing spondylitis pipeline drugs in development in 2022.

 Ankylosing Spondylitis Pipeline Drugs Market Analysis, by Molecule Types

 Ankylosing Spondylitis Pipeline Drugs Market Analysis, by Molecule Types

For more molecule type insights into the ankylosing spondylitis pipeline drugs market, download a free report sample

Ankylosing Spondylitis Pipeline Drugs Market - Competitive Landscape

Some of the leading companies in the ankylosing spondylitis pipeline drugs market are Avesthagen Ltd, Biocad, Bioviz Technologies Pvt Ltd, Bristol-Myers Squibb Co, DNX Biopharmaceuticals Inc, Immunwork Inc, and Mabpharm Ltd.

 Ankylosing Spondylitis Pipeline Drugs Market Analysis, by Companies

 Ankylosing Spondylitis Pipeline Drugs Market Analysis, by Companies

To know more about the companies in the ankylosing spondylitis pipeline drugs market, download a free report sample

Ankylosing Spondylitis Pipeline Drugs Market Report Overview

Key Targets Tumor Necrosis Factor, Interleukin 17A, Lymphotoxin Alpha, Tyrosine Protein Kinase JAK1, Interleukin 17F, Interleukin 17, MAP Kinase Activated Protein Kinase 2, Mitogen Activated Protein Kinase 1, and Granulocyte Macrophage Colony Stimulating Factor
Key Mechanisms of Action Tumor Necrosis Factor Inhibitor, Interleukin 17A Inhibitor, Lymphotoxin Alpha Inhibitor, Tyrosine Protein Kinase JAK1 Inhibitor, Interleukin 17 Inhibitor, Interleukin 17F Inhibitor, and MAP Kinase Activated Protein Kinase 2 Inhibitor
Key Routes of Administration Subcutaneous, Intravenous, Oral, Parenteral, and Topical
Key Molecule Types Monoclonal Antibody, Small Molecule, Fusion Protein, Protein, Small Molecule, Synthetic Peptide, and Others
Leading Companies Avesthagen Ltd, Biocad, Bioviz Technologies Pvt Ltd, Bristol-Myers Squibb Co, DNX Biopharmaceuticals Inc, Immunwork Inc, and Mabpharm Ltd

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ankylosing Spondylitis (Bekhterev’s Disease) (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Ankylosing Spondylitis (Bekhterev’s Disease) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ankylosing Spondylitis (Bekhterev’s Disease) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ankylosing Spondylitis (Bekhterev’s Disease) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ankylosing Spondylitis (Bekhterev’s Disease) (Musculoskeletal Disorders)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ankylosing Spondylitis (Bekhterev’s Disease) (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ankylosing Spondylitis (Bekhterev’s Disease) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

3SBio Inc
AbbVie Inc
Akeso Inc
AstraZeneca Plc
Avesthagen Ltd
Beijing Eastern Biotech Co Ltd
Bio-Thera Solutions Ltd
Biocad
Biogen Inc
Bioviz Technologies Pvt Ltd
BioXpress Therapeutics SA
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Celltrion Inc
Clover Biopharmaceuticals Ltd
DNX Biopharmaceuticals Inc
Dyadic International Inc
Eli Lilly and Co
Enzene Biosciences Ltd
Foshan Rexie Biotechnology Co Ltd
FunPep Co Ltd
Huabo Biopharm (Shanghai) Co Ltd
Hualan Biological Engineering Inc
Iltoo Pharma
Immunwork Inc
Izana Bioscience Ltd
Jiangsu Carephar Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
JiangSu Qyuns Therapeutics Co Ltd
Johnson & Johnson
Livzon Pharmaceutical Group Co Ltd
Luye Pharma Group Ltd
Lynk Pharmaceutical Hangzhou Co Ltd
Mabpharm Ltd
MoonLake Immunotherapeutics
Mycenax Biotech Inc
NeuClone Pty Ltd
Nimbus Therapeutics LLC
North China Pharmaceutical Group New Drug Research and Development Co Ltd
Novartis AG
Outlook Therapeutics Inc
Pharmapraxis
PKU V-Ming (Hefei) Biologics Co Ltd
Qilu Pharmaceutical Co Ltd
Sandoz International GmbH
Shandong Danhong Pharmaceutical Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Novamab Biopharmaceuticals Co Ltd
Siam Bioscience Co Ltd
SinoCelltech Group Ltd
siRNAgen Therapeutics Corp
Suzhou Zelgen Biopharmaceutical Co Ltd
Tianjin Hemay Pharmaceutical Co Ltd
UCB SA
Valin Technologies Ltd
Wuhan Institute of Biological Products Co Ltd
XinThera Inc
Zhejiang Yatai Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Ankylosing Spondylitis (Bekhterev’s Disease) – Overview

Ankylosing Spondylitis (Bekhterev’s Disease) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Ankylosing Spondylitis (Bekhterev’s Disease) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Ankylosing Spondylitis (Bekhterev’s Disease) – Companies Involved in Therapeutics Development

Ankylosing Spondylitis (Bekhterev’s Disease) – Drug Profiles

Ankylosing Spondylitis (Bekhterev’s Disease) – Dormant Projects

Ankylosing Spondylitis (Bekhterev’s Disease) – Discontinued Products

Ankylosing Spondylitis (Bekhterev’s Disease) – Product Development Milestones

Featured News & Press Releases

Aug 17, 2022: NICE Recommends RINVOQ (upadacitinib) as a treatment option for active ankylosing spondylitis (AS) in adults

Jul 27, 2022: Mabpharm announces approval of clinical trial application of CMAB015 by the National Medical Products Administration of China

Jul 21, 2022: Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz (adalimumab-adaz) high concentration formulation (HCF)

Jul 20, 2022: Health Canada approves AbbVie’s RINVOQ® (upadacitinib) for the treatment of adults with active ankylosing spondylitis

Jun 01, 2022: AbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib (RINVOQ®) in Patients with Axial Spondyloarthritis at EULAR 2022

May 02, 2022: FDA grants approval for AbbVie’s Rinvoq to treat ankylosing spondylitis

Apr 11, 2022: Celltrion Healthcare announces the availability of Yuflyma, a high-concentration, low-volume, citrate-free, and latex-free Humira (adalimumab) biosimilar in Canada

Jan 20, 2022: Lynk doses first patient in Phase II ankylosing spondylitis drug trial

Dec 28, 2021: Akeso’s IL-17A monoclonal antibody (Gumokimab) completion of patient enrollment in phase II clinical trial for the treatment of ankylosing spondylitis

Dec 08, 2021: Xinkanghe XKH004 ankylosing spondylitis phase II clinical trial investigator meeting was successfully held

Oct 07, 2021: AbbVie’s RINVOQ (upadacitinib) met primary and all ranked secondary endpoints in phase 3 study in ankylosing spondylitis

Jun 25, 2021: AbbVie provides update regarding RINVOQ (upadacitinib) in psoriatic arthritis and ankylosing spondylitis in the U.S.

Feb 16, 2021: Sandoz Canada completes its 5th biosimilar launch with new biosimilar Hyrimoz (adalimumab)

Jan 25, 2021: European Commission approves AbbVie’s RINVOQ (Upadacitinib) for the treatment of Psoriatic Arthritis and Ankylosing Spondylitis

Dec 22, 2020: China IND application of recombinant anti-human IL-17A/F humanized monoclonal antibody injection for AS indication is accepted by CDE

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Ankylosing Spondylitis (Bekhterev’s Disease), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by 3SBio Inc, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by AbbVie Inc, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Akeso Inc, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by AstraZeneca Plc, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Avesthagen Ltd, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Beijing Eastern Biotech Co Ltd, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Bio-Thera Solutions Ltd, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Biocad, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Biogen Inc, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Bioviz Technologies Pvt Ltd, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by BioXpress Therapeutics SA, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Boehringer Ingelheim International GmbH, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Bristol-Myers Squibb Co, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Celltrion Inc, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Clover Biopharmaceuticals Ltd, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by DNX Biopharmaceuticals Inc, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Dyadic International Inc, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Eli Lilly and Co, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Enzene Biosciences Ltd, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Foshan Rexie Biotechnology Co Ltd, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by FunPep Co Ltd, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Huabo Biopharm (Shanghai) Co Ltd, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Hualan Biological Engineering Inc, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Iltoo Pharma, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Immunwork Inc, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Izana Bioscience Ltd, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Jiangsu Carephar Pharmaceutical Co Ltd, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by JiangSu Qyuns Therapeutics Co Ltd, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Johnson & Johnson, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Livzon Pharmaceutical Group Co Ltd, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Luye Pharma Group Ltd, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Lynk Pharmaceutical Hangzhou Co Ltd, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Mabpharm Ltd, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by MoonLake Immunotherapeutics, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Mycenax Biotech Inc, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by NeuClone Pty Ltd, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Nimbus Therapeutics LLC, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by North China Pharmaceutical Group New Drug Research and Development Co Ltd, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Novartis AG, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Outlook Therapeutics Inc, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Pharmapraxis, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by PKU V-Ming (Hefei) Biologics Co Ltd, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Qilu Pharmaceutical Co Ltd, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Sandoz International GmbH, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Shandong Danhong Pharmaceutical Co Ltd, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Shanghai Novamab Biopharmaceuticals Co Ltd, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Siam Bioscience Co Ltd, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by SinoCelltech Group Ltd, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by siRNAgen Therapeutics Corp, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Tianjin Hemay Pharmaceutical Co Ltd, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by UCB SA, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Valin Technologies Ltd, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Wuhan Institute of Biological Products Co Ltd, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by XinThera Inc, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline by Zhejiang Yatai Pharmaceutical Co Ltd, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Dormant Projects, 2022

Ankylosing Spondylitis (Bekhterev’s Disease) – Dormant Projects, 2022 (Contd..1)

Ankylosing Spondylitis (Bekhterev’s Disease) – Dormant Projects, 2022 (Contd..2)

Ankylosing Spondylitis (Bekhterev’s Disease) – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Ankylosing Spondylitis (Bekhterev’s Disease), 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Ankylosing Spondylitis (Bekhterev’s Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Ankylosing Spondylitis (Bekhterev’s Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Ankylosing Spondylitis (Bekhterev’s Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Ankylosing Spondylitis (Bekhterev’s Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.